The Department of Justice is moving forward with a $1 billion lawsuit against UnitedHealth Group over Medicare claims; Oregon's legislature is considering adding healthcare as a right to the state's constitution; another trial for an Alzheimer disease drug is stopped.
The Department of Justice (DOJ) can move forward with a $1 billion lawsuit against UnitedHealth Group over Medicare claims. According to Reuters, DOJ is claiming the company wrongly retained more than $1 billion related to invalid diagnostic data related to patients in Medicare Advantage plans. The case alleges UnitedHealth submitted inaccurate or untruthful information and obtained inflated payments but failed to repay the Medicare program.
The state House of Representatives in Oregon has endorsed a bill that would make healthcare a right in the state’s constitution. If the Senate also approves the bill, the constitutional amendment would be considered by Oregon voters in November, reported AP. If the state amends its constitution to make healthcare a right, it would be the first in the country to do so. However, opponents pointed to the lack of a plan to fund making healthcare a right and voiced concerns about the potential for lawsuits against the state.
Another drug to treat Alzheimer disease has faced a setback. Merck stopped its final-stage test of verubecestat because it had little or no effect on the disease, according to Bloomberg. Merck was testing the drug under the theory that early treatment could halt damage before it was too late. The drug maker has yet to decide if it will completely end development of the drug. It already has other potential Alzheimer drugs in development.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More